Sartorius Stedim Biotech (OTCMKTS:SDMHF – Get Free Report) is expected to announce its resultson Thursday, July 23rd. Analysts expect Sartorius Stedim Biotech to post earnings of $1.44 per share and revenue of $906.42 million for the quarter.
Sartorius Stedim Biotech Stock Performance
Shares of OTCMKTS:SDMHF opened at $215.50 on Thursday. The stock has a 50 day moving average of $199.96 and a 200 day moving average of $209.67. Sartorius Stedim Biotech has a 12-month low of $178.30 and a 12-month high of $264.30.
About Sartorius Stedim Biotech
Sartorius Stedim Biotech SA (OTCMKTS: SDMHF) is a global provider of bioprocessing equipment and services for the biopharmaceutical industry. The company develops and manufactures technologies that support the development and production of vaccines, monoclonal antibodies, therapeutic proteins and cell‐ and gene‐based therapies. Its solutions address both upstream processes—such as cell cultivation and fermentation—and downstream processes, including filtration, centrifugation and chromatography.
Key product offerings include single‐use bioreactors and mixers, modular filtration assemblies, prepacked chromatography columns, and a wide range of cell culture media and buffer systems.
Recommended Stories
- Five stocks we like better than Sartorius Stedim Biotech
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Sartorius Stedim Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius Stedim Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
